Switch theme
Sign up to access all valuation multiples
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Corestemchemon has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Corestemchemon achieved revenue of $19.6M and an EBITDA of -$15.0M.
Corestemchemon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Corestemchemon valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $22.9M | $19.6M | XXX | XXX | XXX |
| Gross Profit | $10.6M | $2.4M | XXX | XXX | XXX |
| Gross Margin | 46% | 12% | XXX | XXX | XXX |
| EBITDA | -$6.2M | -$15.0M | XXX | XXX | XXX |
| EBITDA Margin | -27% | -77% | XXX | XXX | XXX |
| Net Profit | -$1.8M | -$12.0M | XXX | XXX | XXX |
| Net Margin | -8% | -61% | XXX | XXX | XXX |
| Net Debt | $10.6M | $20.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Corestemchemon's stock price is KRW 3490 (or $2).
Corestemchemon has current market cap of KRW 95.2B (or $64.9M), and EV of KRW 138B (or $93.7M).
See Corestemchemon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93.7M | $64.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Corestemchemon has market cap of $64.9M and EV of $93.7M.
Corestemchemon's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Corestemchemon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Corestemchemon and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $93.7M | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | -6.2x | XXX | XXX | XXX |
| P/E | -3.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCorestemchemon's NTM/LTM revenue growth is n/a
Corestemchemon's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Corestemchemon's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Corestemchemon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Corestemchemon and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -77% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 144% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 44% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 73% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corestemchemon acquired XXX companies to date.
Last acquisition by Corestemchemon was XXXXXXXX, XXXXX XXXXX XXXXXX . Corestemchemon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Corestemchemon founded? | Corestemchemon was founded in 2003. |
| Where is Corestemchemon headquartered? | Corestemchemon is headquartered in South Korea. |
| Is Corestemchemon publicy listed? | Yes, Corestemchemon is a public company listed on KRX. |
| What is the stock symbol of Corestemchemon? | Corestemchemon trades under 166480 ticker. |
| When did Corestemchemon go public? | Corestemchemon went public in 2015. |
| Who are competitors of Corestemchemon? | Similar companies to Corestemchemon include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Corestemchemon? | Corestemchemon's current market cap is $64.9M |
| What is the current revenue growth of Corestemchemon? | Corestemchemon revenue growth between 2023 and 2024 was -15%. |
| Is Corestemchemon profitable? | Yes, Corestemchemon is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
